Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Get Free Report)'s share price rose 8.3% on Monday . The stock traded as high as $2.90 and last traded at $2.88. Approximately 963,991 shares traded hands during mid-day trading, an increase of 25% from the average daily volume of 774,088 shares. The stock had previously closed at $2.66.
Analyst Upgrades and Downgrades
Separately, Cormark upgraded Curaleaf from a "hold" rating to a "moderate buy" rating in a research note on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Strong Buy".
Get Our Latest Research Report on Curaleaf
Curaleaf Price Performance
The stock has a market capitalization of $1.89 billion, a PE ratio of -8.81 and a beta of 0.69. The stock's 50 day moving average is $1.46 and its two-hundred day moving average is $1.16. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.70 and a current ratio of 1.47.
Curaleaf (OTCMKTS:CURLF - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.01. Curaleaf had a negative net margin of 18.08% and a negative return on equity of 14.61%. On average, equities analysts anticipate that Curaleaf Holdings, Inc. will post -0.25 EPS for the current fiscal year.
About Curaleaf
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Featured Stories
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.